- Home
- WVE
as of 03-09-2026 3:55pm EST
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
| Founded: | 2012 | Country: | Singapore |
| Employees: | N/A | City: | SINGAPORE |
| Market Cap: | 2.4B | IPO Year: | 2015 |
| Target Price: | $30.87 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | -72.86 |
| 52 Week Low/High: | $5.28 - $21.73 | Next Earning Date: | 05-29-2026 |
| Revenue: | $3,704,000 | Revenue Growth: | 149.43% |
| Revenue Growth (this year): | -9.74% | Revenue Growth (next year): | 119.93% |
| P/E Ratio: | -10.84 | Index: | N/A |
| Free Cash Flow: | -188211000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Wave Life Sciences Ltd. (WVE)
See Remarks
Avg Cost/Share
$13.45
Shares
1,883
Total Value
$25,326.35
Owned After
61,867
SEC Form 4
President and CEO
Avg Cost/Share
$13.45
Shares
10,480
Total Value
$140,956.00
Owned After
275,520
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$13.45
Shares
3,588
Total Value
$48,258.60
Owned After
134,385
SEC Form 4
See Remarks
Avg Cost/Share
$13.45
Shares
3,228
Total Value
$43,416.60
Owned After
408,246
SEC Form 4
See Remarks
Avg Cost/Share
$16.31
Shares
9,375
Total Value
$150,260.10
Owned After
61,867
Chief Financial Officer
Avg Cost/Share
$20.14
Shares
50,036
Total Value
$1,001,979.00
Owned After
134,385
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Francis Chris | WVE | See Remarks | Feb 9, 2026 | Sell | $13.45 | 1,883 | $25,326.35 | 61,867 | |
| BOLNO PAUL | WVE | President and CEO | Feb 9, 2026 | Sell | $13.45 | 10,480 | $140,956.00 | 275,520 | |
| Moran Kyle | WVE | Chief Financial Officer | Feb 9, 2026 | Sell | $13.45 | 3,588 | $48,258.60 | 134,385 | |
| Vargeese Chandra | WVE | See Remarks | Feb 9, 2026 | Sell | $13.45 | 3,228 | $43,416.60 | 408,246 | |
| Francis Chris | WVE | See Remarks | Jan 2, 2026 | Sell | $16.31 | 9,375 | $150,260.10 | 61,867 | |
| GSK plc | WVE | 10% Owner | Dec 11, 2025 | Buy | $19.00 | 1,470,000 | $27,930,000.00 | 18,245,691 | |
| Moran Kyle | WVE | Chief Financial Officer | Dec 9, 2025 | Sell | $20.14 | 50,036 | $1,001,979.00 | 134,385 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-3.62%
$14.80
5D
-8.51%
$14.05
20D
-9.09%
$13.96
8-K
false 0001631574 0001631574 2026-02-26 2026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
Singapore
001-37627
98-1356880
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
7 Straits View #12-00, Marina One
East Tower
Singapore
018936
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on which registered
$0 Par Value Ordinary Shares
WVE
The Nasdaq Global Market
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 7.01 Regulation FD Disclosure.
From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On February 26, 2026, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K The information in these Items 2.02 and 7.01 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits The following exhibits relating to Items 2.02 and 7.01 are furnished and not filed:
Exhibit No.
Description
99.1
Press Release issued by Wave Life Sciences Ltd. dated February 26, 2026
99.2
Corporate Presentation of Wave Life Sciences Ltd. dated February 26, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WAVE LIFE SCIENCES LTD.
By:
/s/ Kyle Moran
Kyle Moran
Chief Financial Officer
Date: February 26, 2026
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-3.62%
$14.80
5D
-8.51%
$14.05
20D
-9.09%
$13.96
8-K
7 Straits View #12-00 false 0001631574 0001631574 2026-01-12 2026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
Singapore
001-37627
98-1356880
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
7 Straits View #12-00, Marina One
East Tower Singapore
018936
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on which registered
$0 Par Value Ordinary Shares
WVE
The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 12, 2026, Wave Life Sciences Ltd. (the “Company”) issued a press release and updated its corporate presentation, as described further under Item 7.01 below, each of which included a preliminary, unaudited estimate of the amount of its cash and cash equivalents as of December 31, 2025. The Company preliminarily estimates that its cash and cash equivalents as of December 31, 2025 were approximately $602 million. A copy of the press release and corporate presentation are furnished as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, respectively. The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amount included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025.
Item 7.01. Regulation FD Disclosure.
From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On January 12, 2026, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in these Items 2.02 and 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits The following exhibits relating to Items 2.02 and 7.01 are furnished and not filed:
Exhibit No.
Description
99.1
Press Release issued by Wave Life Sciences Ltd., dated January 12, 2026.
99.2
Corporate Presentation of Wave Life Sciences Ltd., dated January 12, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WAVE LIFE SCIENCES LTD.
By:
/s/ Kyle Moran
Kyle Moran
Chief Financial Officer
Date: January 12, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
Q3 2025 Earnings
8-KNov 10, 2025
8-K
7 Straits View #12-00 false 0001631574 0001631574 2025-11-10 2025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
Singapore
001-37627
98-1356880
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
7 Straits View #12-00, Marina One
East Tower Singapore
018936
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on which registered
$0 Par Value Ordinary Shares
WVE
The Nasdaq Global Market
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2025, Wave Life Sciences Ltd. announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits The following exhibit relating to Item 2.02 is furnished and not filed:
Exhibit No.
Description
99.1
Press Release issued by Wave Life Sciences Ltd. dated November 10, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WAVE LIFE SCIENCES LTD.
By:
/s/ Kyle Moran
Kyle Moran
Chief Financial Officer
Date: November 10, 2025
Compare WVE vs Leading Stocks
See how WVE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "WVE Wave Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.